Best Startup
At Best Startup US we track over 1,000,000 US startups and over 3 million people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United States based Director operating in the Health Diagnostics space. If you think a Director is missing from this list, feel free to contact our editor on editor@beststartup.us.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Robert Nelsen
Co-Founder & Managing Director of ARCH Venture Partners
Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners. He joined ARCH at its founding and played a significant role in the early sourcing, financing and development of more than 100 companies, including nineteen which have reached valuations exceeding $1 billion. His seed and early-stage investments include Illumina (ILMN); Alnylam Pharmaceuticals (ALNY); Juno Therapeutics (JUNO); Unity Biotechnology (UBX); Sienna Biopharmaceuticals (SNNA); Vir Biotechnology, Agios Pharmaceuticals (AGIO); Sage Therapeutics (SAGE); GRAIL, Ikaria; Kythera Biopharmaceuticals (KYTH), Receptos (RCPT); Aviron (AVIR); Denali Therapeutics (DNLI); Rubius Therapeutics, KSQ Therapeutics, Beam Therapeutics, NetBot; Bluebird Bio (BLUE); R2 Technology; XenoPort (XNPT); Caliper Life Sciences (CALP); Trubion Pharmaceuticals (TRBN); Adolor (ADLR); deCODE Genetics; Array BioPharma (ARRY); Editas (EDIT), IDUN Pharmaceuticals; Classmates.com; Hua Medicine; Fate Therapeutics (FATE); WuxiNextCODE; and Everyday Learning Corporation. Mr. Nelsen is a director of Vir Bio, GRAIL, Sienna Biopharmaceuticals, Beam Therapeutics, Unity Biotechnology, Denali Therapeutics, Arivale, Syros Pharmaceuticals, and serves as Chairman of Hua Medicine, among others. He previously served as a Trustee of the Fred Hutchinson Cancer Research Institute, the Institute for Systems Biology, and was a director of the National Venture Capital Association. Mr. Nelsen holds an M.B.A. from the University of Chicago and a B.S. from the University of Puget Sound with majors in Economics and Biology.
Follow Robert Nelsen:
About ARCH Venture Partners: ARCH is an early-stage venture firm that focuses on life science discoveries to prevent, detect, and cure disease.
_______
Keith Crandell
Founder and Managing Director of ARCH Venture Partners
Keith L. Crandell is the Co – Founder & Managing Director, ARCH Venture Partners. He focuses on chemical and specialty materials companies, electronics and instrumentation, optics and photonics, communications, and enterprise infrastructure businesses. He previously served as Senior Manager at ARCH Development Corporation, where he was responsible for ARCH Venture Fund I activities at Argonne National Laboratory. Mr. Crandell has played a key role in the formation and initial funding round of Quanterix, Alfalight, PixelEXX Systems, ALIS Corp. (acquired by Carl Zeiss SMT), Eichrom Industries (acquired by Gary Comer, Inc.), Nanophase Technologies (NANX), and Illinois Superconductor. He was also responsible for ARCH’s investment in New Era of Networks (NEON, acquired by Sybase-SY), Apropos Technology (APRS, acquired by Syntellect-ESL), Teach.com (acquired by Intellinex), CelebrateExpress (BDAY, acquired by Liberty Media-LINTA), Ahura Scientific (acquired by Thermo Fisher Scientific-TMO), Adesto Technologies, Ciespace, Boreal Genomics, and Crystal IS (acquired by Asahi Kasei-AHKSY), among others. He is a Director of Quanterix, Nanosys, Alfalight, Adesto Technologies, Boreal Genomics, PixelEXX Systems, Univa, Ciespace. Mr. Crandell also serves as a Director of the Illinois Venture Capital Association. Prior to the founding of ARCH, Mr. Crandell was with the specialty chemical and polymer company, Hercules, Inc. He holds an M.B.A. from The University of Chicago. An M.S. in Chemistry from the University of Texas at Arlington. B.S. in Chemistry and Mathematics from St. Lawrence University.
Follow Keith Crandell:
About ARCH Venture Partners: ARCH is an early-stage venture firm that focuses on life science discoveries to prevent, detect, and cure disease.
Kristina Burow
Managing Director of ARCH Venture Partners
Kristina Burow is a Managing Director with ARCH Venture Partners. Kristina Burow is focused on the creation and development of biotechnology, pharmaceutical and agbiotechnology companies.
Follow Kristina Burow:
About ARCH Venture Partners: ARCH is an early-stage venture firm that focuses on life science discoveries to prevent, detect, and cure disease.
Steven Gillis
Managing Director of ARCH Venture Partners
Steven Gillis is a Managing Director with ARCH, joining the firm as a Venture Partner in 2005. Steven is focused on the evaluation of new life science technologies and also on the development and growth of ARCH’s biotechnology portfolio companies. Steven is a Member of the Board of Directors at Homology Medicines, Inc., Allozyne, Pulmatrix (PULM), Codiak Biosciences, Faraday Pharmaceuticals, Just. Biotherapeutics, VLST, Lodo Therapeutics and Accelerator. Steven serves as Member of the Board of Directors and Chairman of the Board of Directors at VentiRx Pharmaceuticals, Theraclone Sciences, Lycera, VBI Vaccines (VBIV) and PhaseRx. Steven was a Founder and a Member of the Board of Directors at Corixa Corp. and served as Chief Executive Officer from its inception and as its Chairman of the Board of Directors from 1999 until its acquisition in 2005 by GlaxoSmithKline. Prior to Corixa, Stevens was a Founder and Member of the Board of Directors at Immunex Corp., the most successful venture-funded biotech company in the state of Washington. From 1981 until his departure in 1994, Steven served as Immunex’s Director of Research and Development, Chief Scientific Officer and as Chief Executive Officer of Immunex’s R&D subsidiary. Steven was interim Chief Executive Officer of Immunex Corp. following its majority purchase by American Cyanamid Co. and remained a Member of the Board of Directors until 1997. Amgen, Inc. acquired Immunex in 2002. Steven is an immunologist by training with over 300 peer-reviewed publications in the areas of molecular and tumor immunology. Steven is credited as being a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products including Leukine, (GM-CSF), Prokine (IL-2) and Enbrel (soluble TNF receptor-Fc fusion protein) as well as the regulatory approval of Bexxar (radiolabeled anti-CD20). Steven received a B.A. degree from Williams College and a Ph.D. from Dartmouth College.
Follow Steven Gillis:
About ARCH Venture Partners, Geisel School of Medicine at Dartmouth, Theraclone Sciences, Tuck School of Business at Dartmouth College: ARCH is an early-stage venture firm that focuses on life science discoveries to prevent, detect, and cure disease.
Clinton Bybee
Co-Founder and Managing Director of ARCH Venture Partners
Clinton Bybee is a co-founder and Managing Director of ARCH Venture Partners. Mr. Bybee concentrates primarily on advanced materials, electronics, semiconductors, photonics, and infrastructure businesses. Mr. Bybee has helped organize and finance numerous companies including MicroOptical Devices (acquired by EMCORE), Cambrios Technologies, Aveso, Innovalight, Intelligent Reasoning Systems (acquired by Photon Dynamics), Semprius, Nanosys, and Xtera Communications. He is a board member of Impinj, Innovalight, Cambrios Technologies, Xtera Communications, Nitronex and Aveso. Mr. Bybee is an organizing member of the Texas Venture Capital Association and currently serves as its first President. Previously, Mr. Bybee worked with ARCH Development Corporation. He also managed a venture investment fund for the State of Illinois and was a production engineer with Amoco Corporation.
Follow Clinton Bybee:
About ARCH Development Corporation, ARCH Venture Partners, Nitronex: ARCH is an early-stage venture firm that focuses on life science discoveries to prevent, detect, and cure disease.
Steven Lazarus
Co-founder and Managing Director, Emeritus Chicago of ARCH Venture Partners
Steven Lazarus is a co-founder and Managing Director, Emeritus of ARCH Venture Partners. He also is a director of the Rand Corporation. Prior to the founding of ARCH Venture Partners, Mr. Lazarus served as CEO of ARCH Development Corporation and as Associate Dean of the Graduate School of Business of the University of Chicago. He previously spent 13 years with Baxter Laboratories in various senior roles, lastly as Group Vice President of the Health Care Services Group of Baxter Travenol Laboratories. Mr. Lazarus also served in Washington D.C. as Deputy Assistant Secretary of Commerce for East-West Trade for the U.S., a government bureau he both founded and directed. Mr. Lazarus is a 21-year veteran of the U.S. Navy, retiring with the rank of Captain in 1973. Mr. Lazarus received an M.B.A. with high distinction from the Harvard Graduate School of Business and holds an A.B. with Honors from Dartmouth College.
Follow Steven Lazarus:
About ARCH Venture Partners, RAND: ARCH is an early-stage venture firm that focuses on life science discoveries to prevent, detect, and cure disease.
Daniel Wilcox
Director of Member Care of Ro
Follow Daniel Wilcox:
About Ro: Ro is a telehealth startup that operates digital health clinics for men’s and women’s health, along with smoking cessation.
Donald Ehrlich
Member of the Board of Directors of Danaher
Donald Ehrlich has served on Danaher’s Board of Directors since 1985. He served as President and Chief Executive Officer of Schwab Corp., a manufacturer of fire-protective safes, files, cabinets and vault doors, from January 2003 to July 2008, and has also served on the boards of private and non-profit organizations. Donald also founded and served as the chairman and chief executive officer of an NYSE-listed, publicly-traded manufacturing company, and has also founded and served as CEO of two privately held manufacturing companies. As an entrepreneur and business leader who began his career on the factory floor, has been awarded over fifteen patents and worked his way to leadership of a large, publicly-traded company, Donald has a broad understanding of the strategic challenges and opportunities facing a publicly-traded manufacturing company such as Danaher. He also has a broad, functional skill-set in the areas of engineering, finance, capital allocation and executive compensation
Follow Donald Ehrlich:
About : Danaher is a global science and technology innovator committed to helping their customers solve complex challenges and improve quality.
Walter Lohr
Member of the Board of Directors of Danaher
Walter Lohr has served on Danaher’s Board of Directors since 1983. He was a partner of Hogan Lovells, a global law firm, for over five years until retiring in June 2012 and has also served on the boards of private and non-profit organizations. Prior to his tenure at Hogan Lovells, Walter served as assistant attorney general for the State of Maryland.He has extensive experience advising companies in a broad range of transactional matters, including mergers and acquisitions, contests for corporate control and securities offerings. His extensive knowledge of the legal strategies, issues and dynamics that pertain to mergers and acquisitions and capital raising have been a critical resource for Danaher given the importance of its acquisition program.
Follow Walter Lohr:
About : Danaher is a global science and technology innovator committed to helping their customers solve complex challenges and improve quality.
Justin Holland
Senior Director of Danaher
Follow Justin Holland:
About Danaher: Danaher is a global science and technology innovator committed to helping their customers solve complex challenges and improve quality.
Gregory Hinckley
Lead Director of Bio-Rad Laboratories
Hinckley has been President of the Company since 2000, and was Executive Vice President, Chief Operating Officer and Chief Financial Officer of the Company from 1997 to 2000. He continued to function as the Company’s Chief Financial Officer from 2000 to July 2007, and again became the Chief Financial Officer in December 2008. He is a director of Intermec, Inc. (a provider of integrated system solutions), Super Micro Computer, Inc. (a server board, chassis and server systems supplier), and SI Bone, Inc. (a privately held medical device company). Until 2007, Hinckley was also a director of Amkor Technology, Inc. (a provider of semiconductor packaging and test services). Prior to joining Mentor, Hinckley was Vice President, and then Senior Vice President, of VLSI Technology, Inc. (a semiconductor company) from 1992 to 1997.
Follow Gregory Hinckley:
About Bio-Rad Laboratories: Bio-Rad Laboratories has played a leading role in the advancement of scientific discovery for over 50 years by providing a broad range of
Sylvana Quader Sinha
Founder, Managing Director and CEO of Praava Health
Sylvana Q. Sinha is founder and CEO of Praava Health, a leading healthcare company focused on improving health outcomes and patient journeys in emerging markets, where 85% of the world lives but whose current systems typically prioritize profits over patients.
Since launching in 2018, Praava has become Bangladesh’s fastest-growing consumer healthcare brand, and was designated a 2021 World Economic Forum Technology Pioneer and 2020 Fast Company World Changing Idea and Developing World Technology. Praava has served more than 300,000 patients and is tripling growth each year. Throughout the COVID-19 pandemic, Praava quadrupled its patient base while maintaining an NPS rating of 91.3—significantly exceeding even the highest scores of Fortune 500 companies.
Sylvana also has decades of experience leading teams in international law, business, development, and government relations at major international law firms, management consulting firms, the World Bank, and think tanks in the Middle East and S. Asia. In addition to serving as an advisor to then-Senator Obama, she has independently advised private and sovereign clients on investments, projects, and disputes in the Middle East, Africa, and S. Asia.
Sylvana is a Life Member of the Council on Foreign Relations, a member of the World Economic Forum’s UHC2030 Private Sector Constituency, and served on Mount Sinai’s Arnold Institute of Global Health Task Force for Global Advantage. She is a graduate of Columbia Law School, Harvard’s Kennedy School, and Wellesley College and was a Visiting Scholar at the University of Oxford.
Follow Sylvana Quader Sinha:
About Praava Health: Praava Health is a patient-driven company disrupting the healthcare standard for Bangladesh’s 170 million citizens.
Peng Yin
Co-Founder, Director of NuProbe
Peng is a Professor in the Department of Systems Biology at Harvard Medical School. He also serves as a Core Faculty member of the Wyss Institute for Biologically Inspired Engineering at Harvard University, where he co-founded Ultivue. Co-Founder, Director at Torus Biosystems.
Follow Peng Yin:
About Harvard Medical School, NuProbe, Torus Biosystems, Ultivue, Wyss Institute: An early stage molecular diagnostics company.
Ilan Kaufthal
Director of Bio-Reference Laboratories
Ilan Kaufthal served as a Senior Advisor at Irving Place Capital from July 2008 to July 2013. Mr. Kaufthal has over 30 years of experience as an investment banker and senior corporate executive. He joined Irving Place Capital in 2008 and focused on retail and consumer products. He joined Bear, Stearns & Co. Inc. in May 2000 and served eight years there as the Vice Chairman of Investment Banking from May 2000 to July 2008. Mr. Kaufthal served as the Head of Mergers and Acquisitions as the Vice Chairman of Schroder & Co. for 13 years and a Managing Director from February 1987 to March 1997. He served as the Vice Chairman of Schroder & Co. Inc. from April 1997 to May 2000. He served at Schroder, and PROTEAM.com, Inc. He served as the Chief Financial Officer and Senior Vice President at NL Industries Inc. from May 1971 to February 1987. He served as the Chairman of East Wind Advisors, LLC since May 2011. Mr. Kaufthal has been a Director of Cambrex Corporation since 1983; and Blyth, Inc. since February 24, 2012. He serves as a Director of Edmunds.com, Inc. He serves as the Chairman of the American Friends of Bezalel. He serves as a Member of the Board of Visitors of Columbia University Medical Center. He serves as a Member of the Trustee Council of The Jewish Museum, Ramaz School in New York City and The Russell Berrie Foundation. He serves as a Non-Management Director of Fairfield Resorts, Inc. and Wyndham Vacation Resorts, Inc. He serves as a Director of Cambrex Profarmaco Landen N.V. He has been a Director of Bio-Reference Laboratories Inc. since March 3, 2015. He has been Director of Quinpario Acquisition Corp. 2 since November 2014. He has been a Director of Tronox Limited since June 15, 2012. He served as an Independent Director of Jason Industries, Inc. from August 2013 to June 30, 2014. He served as Director of PROTEAM.com, Inc. He served as a Director of Phytomedics, Inc. since August 2006, ASI Solutions, Inc. since joining in 1996, United Retail Group, Inc. from December 1992 to November 8, 2007, and Kid Brands, Inc. (alternate name, Russ Berrie & Co. Inc.) from 1995 to August 2006. He served as a Member of the Advisory Board of Gemini Israel Funds and Jerusalem Venture Partners Media Fund. Mr. Kaufthal holds an M.B.A. Degree from the New York University Graduate School of Business Administration and a B.A. from Columbia University.
Follow Ilan Kaufthal:
About Bio-Reference Laboratories: BioReference is the third largest full service clinical diagnostic laboratory in the U.S. providing testing .
Daniel Birtwhistle
Senior Director Product Development Security of GE Healthcare
Follow Daniel Birtwhistle:
About GE Healthcare: GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care.
Stanley Lapidus
Board of Directors of Daktari Diagnostics
He is an experienced entrepreneur. He founded and served as CEO of three public companies, Cytyc, EXACT Sciences, and Helicos BioSciences. He currently serves as CEO of SynapDx Corp., which he founded in 2009 to develop novel diagnostics for autism. He teaches at the Biomedical Enterprise Program at MIT and is the inventor of 31 US patents.
Follow Stanley Lapidus:
About University of Colorado Anschutz Medical Campus: Daktari Diagnostics manufactures diagnostic medical products for clinicians and patients.
Johannes Fruehauf
Founder, President & Executive Director of LabCentral
Johannes Fruehauf is the Founder & CEO LabCentral/Biolabs.He is responsible for all aspects of LabCentral’s operation. Johannes is a physician and successful biotech entrepreneur. Prior to LabCentral, he founded Cambridge Biolabs, a contract research facility serving startup and virtual companies in Kendall Square. He is also a co-founder of ViThera Pharmaceuticals, Deltix and Cequent Pharmaceuticals, and an advisor or board member to numerous life sciences companies and non-profits. Johannes earned his medical degree at the University of Frankfurt and his PhD at the University of Heidelberg (Germany).
Follow Johannes Fruehauf:
About Arkuda Therapeutics, BioLabs, Cequent Pharmaceuticals, Deltix, LabCentral, Mission BioCapital: LabCentral developing novel cancer treatments: Conkwest, Inc, headquartered in DelMar, California, is opening its research laboratory at
Michael Bartholomew
Co-Founder, Inside Director & Chief Commercial Officer of Promaxo
Mr. Michael Bartholomew is the EVP and Chief Commercial Officer at Promaxo. He has broad therapeutic experience across nearly twenty diseases covering large and small molecules, medical devices and diagnostics. Michael manages the go to market strategy, voice of customer, partner relationships and tactical implementation relating to corporate infrastructure. Prior to Promaxo, Michael was a Principal at Porzio Life Sciences, as well as Vice President of Sales & Marketing for Dohmen Life Science Service, where he developed and launched several commercial initiatives achieving sustained sales growth. Before Dohmen, he served in various sales and brand leadership positions for Pfizer, Pharmacia and Baxter. Michael proudly served in the US Air Force as a decorated combat aviator, where he achieved the rank of Captain. He received his Masters of Science in Administration from Central Michigan University and his Bachelor of Arts in Economics from Indiana University.
Follow Michael Bartholomew:
About Neuro42, Promaxo: Promaxo is commercializing customer-centric MRI systems and robotic guidance tools for live diagnosis and treatment in a physician’s office.
Azim Munivar
Medical Director of Biohaven Pharmaceutical
Azim Munivar is the Medical Director at Biohaven Pharmaceutical.
Follow Azim Munivar:
About Biohaven Pharmaceutical: Biohaven is engaged in the identification and development of clinical stage neuroscience compounds targeting the glutamatergic system.
Jenny Rooke
Founder & Managing Director of Genoa Ventures
Dr. Jenny Rooke has been deploying capital at the frontiers of life sciences innovation, with a penchant for technology-fueled solutions and category-defying opportunities. Jenny got her start in venture at Fidelity Biosciences, a Cambridge-based healthcare VC, during their Fund I formation. Jenny then brought her unique toolkit of genetics domain expertise, strategic business acumen, and venture investing to the Gates Foundation, where she deployed and managed over $250M in funding in genetic engineering, diagnostics, and synthetic biology. She also played a key role in establishing the foundation’s investing function. In 2014, Dr. Rooke began independently investing under the brand 5 Prime Ventures, financing her investments using what has become the largest life sciences syndicate on AngelList, and one of the highest-performing AngelList syndicates of any sector. Jenny founded Genoa Ventures in 2018, building on the 5 Prime Ventures track record, in order to scale a proven, differentiated investing strategy, to ensure continued access to the very best deals, and to maximize portfolio returns.
Follow Jenny Rooke:
About Genoa Ventures: Genoa Ventures is a venture capital firm that invests in early-stage life sciences technology companies.
Susan Wills
Director Strategic Sourcing and Contracts of Dana-Farber Cancer Institute
Susan Wills is the Director of Strategic Sourcing and Contracts for the Dana-Farber Cancer Institute in Boston, Massachusetts. She has been in her current position for five years. Susan has worked as the Director of Materials Management, covering departments such as purchasing, contracts, sterile central, courier, mailroom, print shop, medical equipment management, patient transport, warehouse, receiving and inventory control, for over 25 years in both Massachusetts and New Hampshire community hospitals. Susan has been a member of AHRMM since 1992, has been a CMRP since 2002 and recently received her Fellow status in May 2016. She has served on the AHRMM Educational Committee and has supported the New England Society of Healthcare Materials Management (NESHMM). She currently serves on the NESHMM Educational Committee.
Follow Susan Wills:
About Dana-Farber Cancer Institute: Dana-Farber Cancer Institute is a center dedicated to carrying out adult and pediatric cancer treatment activities and advanced research.
James Cheng
Senior Associate Director, Analytics, Prospect Research of Dana-Farber Cancer Institute
James Cheng currently holds the position of Associate Director of Analytics in Development Research at Dana-Farber Cancer Institute. Like many folks in development research, James’ background is not directly related to philanthropy. Besides resource development, he’s made intellectual and professional forays into cell and development biology, secondary science education, as well as educational research, measurement, and evaluation. While finishing up a doctorate degree in applied statistics in education at Boston College, James’ interest in development was piqued when he also took on the role of Prospect Data Mining and Modeling Specialist at MIT from 2006 to 2008. After spending time in the corporate world as a healthcare market researcher, James returned to the philanthropic sector, working at Dana-Farber Development & The Jimmy Fund since January of 2011.
Follow James Cheng:
About Dana-Farber Cancer Institute: Dana-Farber Cancer Institute is a center dedicated to carrying out adult and pediatric cancer treatment activities and advanced research.
Joseph Authement
US Director Strategic Accounts-Robotics and Digital Solutions of Johnson & Johnson
Follow Joseph Authement:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Alice Lin Fabiano
Global Director of Social Innovation & Investment, Global Community Impact of Johnson & Johnson
Alice Lin Fabiano is a Global Director at Johnson & Johnson, Global Community Impact. In this capacity, she leads its social innovation strategy and investments in the discovery, engagement, and celebration of purpose driven entrepreneurs, with a focus in health technology and impact investing.
Follow Alice Lin Fabiano:
About Johnson & Johnson, Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Daniel Watts
Director, Global Process Owner, Global Contracting Solutions of Johnson & Johnson
Follow Daniel Watts:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Hari Kamaraju
Director and Head of Manufacturing Excellence, Advanced Therapies of Johnson & Johnson
Follow Hari Kamaraju:
About Janssen Belgium, Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Bret Evans
Sr Director IT of Johnson & Johnson
Currently Bret is the Sr. Director of IT Supply Chain for Johnson & Johnson Ethicon & CSS business.
Follow Bret Evans:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Rick Desmarais
Director Global JJOS Deployment Leader of Johnson & Johnson
Follow Rick Desmarais:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Joy Marini
Director of Corporate Contributions of Johnson & Johnson
Joy Marini became Director of Corporate Contributions in 2007, following 6 years with the Johnson & Johnson Pediatric Institute. Joy is responsible for Johnson & Johnson’s international programs on maternal and infant health, gender-based violence and gender inequality, and economic empowerment of women. She has been instrumental in developing sustainable partnership initiatives, most notably for her efforts on a Neonatal Resuscitation Program (NRP) in China — a 5-year collaboration between the Chinese Ministry of Health, the American Academy of Pediatrics (AAP), several Chinese health-professional organizations, and Johnson & Johnson, which reduced neonatal mortality by 54% in over 300 measured hospitals. Joy has contributed to the development of publications for parents and health professionals, including the Compendium of Postpartum Care with the Association of Women’s Health, Obstetrics and Neonatal Nursing, and Eating Behaviors of the Young Child with the AAP. Joy earned her MS Physician Assistant from the University of Medicine and Dentistry of New Jersey in 1997. She received an MBA from Rider University.
Follow Joy Marini:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Ravi Bhatia
Scientific Director of Johnson & Johnson
Follow Ravi Bhatia:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Reggie Fortson
Director of Product Lifecycle Management (PLM) of Johnson & Johnson
Follow Reggie Fortson:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Susan Can
Senior Director & Global Corporate Brand and Corporate Affairs of Johnson & Johnson
Follow Susan Can:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Susan Can
Senior Director & Global Corporate Brand and Corporate Affairs of Johnson & Johnson
Follow Susan Can:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Gregory Smith
IT Director, I&AM Engineering of Johnson & Johnson
Follow Gregory Smith:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Ilya Shestopalov
Director of Bluebird Bio
Follow Ilya Shestopalov:
About Bluebird Bio, Bluebird Bio: Bluebird Bio offers products based on the transformative potential of gene therapy for patients with genetic and orphan diseases.
Ping Gao
Center Director of Abbott
Follow Ping Gao:
About Abbott: Abbott is engaged in pharmaceuticals and manufacturing healthcare products.
Caroline Leab
Director, R&D of Abbott
Caroline Leab is a Director of Regulatory Affairs for Abbott, formerly St. Jude Medical. Caroline leads the EU MDR Implementation Program and Clinical Evaluation Process for the Abbott Cardiovascular and Neuromodulation organization. She has a background in Manufacturing and Quality Engineering with companies such as Boston Scientific and Nestle Healthcare Nutrition. Caroline led Quality organizations for AGA Medical and Monteris Medical before joining St. Jude Medical as a Director of R&D in 2014. Caroline serves on the Board of Directors for The Bakken Museum in Minneapolis and participates on various MDIC and AdvaMed committees.
Follow Caroline Leab:
About Abbott: Abbott is engaged in pharmaceuticals and manufacturing healthcare products.
Barry Simon
Director & Chief Corporate Affairs Officer of ImmunityBio
Dr. Simon served as ImmunityBio’s President and CEO from 2007 to 2015, and is currently a Director and CCAO. Dr. Simon is also a Director and the Chairman of the Compensation Committee at Cue BioPharma and Viracta Therapeutics. Dr. Simon has worked at F. Hoffmann-La Roche, Roche Labs, Connetics Corp., Immunomedics, Immusol, NorthSound Capital, LLC, and HealthPro BioVentures as a Vice President, senior level, and advisory role. Dr. Simon has extensive expertise in both the public and private sectors, having led product and portfolio divestitures and acquisitions, strategic licensing and joint ventures, commercial product launches, IND & BLA regulatory submissions, and life cycle management. Dr. Simon worked in a variety of therapeutic areas, including cancer, virology, and dermatology, and on the introduction of eight medications. Dr. Simon completed corporate training programs at the London School of Business and Dartmouth College’s Amos Tuck School of Business. Dr. Simon got his M.D. from the SUNY Downstate Health Sciences Center in New York and completed clinical training in Infectious Diseases, Anesthesiology, and Internal Medicine.
Follow Barry Simon:
About ImmunityBio, NantKwest: ImmunityBio is an offshoot of Soon-Shiong’s NantWorks conglomerate, developing molecular-level cell-based treatments for diseases.
Colton Pierson
Director Of Engineering of Curative
Follow Colton Pierson:
About Curative: Curative is a leader in on-demand public health programs and infrastructure. We’re building a healthier tomorrow, together.
Shantanu Nundy
Director of Human Diagnosis Project
Follow Shantanu Nundy:
About Accolade, George Washington University, Human Diagnosis Project: Human Diagnosis Project is a worldwide effort to build an online system that maps the best steps to help any patient.
Ralph Taylor-Smith
Managing Director of GE Ventures
Ralph is a Managing Director of Investing. He is based in Washington, DC, and joined the team in 2014. In collaboration with GE’s business units, he leads financial investments in innovative sensors, robotics, and data-com technologies for applications in factory automation, advanced manufacturing services, and digital health. Before joining GE Ventures, Ralph was Cofounder, General Partner, and Managing Director for Battelle Venture Partners and an Investment Banker in M&A for Goldman Sachs and JP Morgan. Previously, he worked at Bell Labs as a senior research scientist, engineer, and business development manager in hardware, software, and nanotech-enabled IT devices within the photonics and semiconductor microelectronics industry. He has a PhD and a master’s degree from Princeton University, as well as master’s and bachelor’s degrees from the Massachusetts Institute of Technology. Ralph is a board member of Sarcos, Inc., Omni-ID, Inc., Xometry, Inc., Clearpath Robotics, Ltd., and Upskill, Inc. Ralph’s athletic pursuits include scuba diving and épée fencing.
Follow Ralph Taylor-Smith:
About GE Ventures: GE Ventures combines capital, expertise, infrastructure, and the GE global network to help accelerate the growth of businesses.
Jessica Zeaske
Director of Healthcare Investments of GE Ventures
ssica Zeaske began her career writing software for a start-up health care delivery company. She moved to a merchant bank, Greenspring Advisors, where she worked exclusively with companies in the health care services sector. She developed experience in licensing and intellectual property management as Start-up Manager at Oregon Health and Science University and as Associate Director and co-founder of the Venture Center at the University of Minnesota. Jessica has an MBA from Regis University, a Master’s degree and Ph.D. from the Johns Hopkins University School of Public Health, and an undergraduate degree with honors from Stanford University. She is a past board member of OneHealth Solutions and currently serves on the board of PlanSource.
Follow Jessica Zeaske:
About Boston Medical Center, Echo Health Ventures, GE Ventures, Lemhi Ventures: GE Ventures combines capital, expertise, infrastructure, and the GE global network to help accelerate the growth of businesses.
Daniel Hullah
Managing Director of GE Ventures
Daniel was born and educated in the UK where he received a BA and a PhD in Chemistry from the University of Oxford. He came to the United States in 1999 as a postdoctoral research associate at the University of Chicago. Following his stint in Chicago, Daniel left academia but stayed in the States as he branched out into a career in management consulting at ZS Associates – a firm that focuses exclusively on sales and marketing. Daniel moved to Boston in 2001 to start a new ZS office, and went on to pursue an MBA at INSEAD in Fontainebleau, France. Shortly after returning to the States from INSEAD, Daniel joined RockPort in Boston. Since then he has been an active member of the screening and diligence team and has worked on multiple transactions in several key cleantech sectors most notably solar energy and green buildings. He has represented RockPort on investor panels at conferences throughout the country.
Follow Daniel Hullah:
About GE Ventures: GE Ventures combines capital, expertise, infrastructure, and the GE global network to help accelerate the growth of businesses.
Joshua Paradise
Director, Strategic Marketing of GE Ventures
Follow Joshua Paradise:
About GE Ventures: GE Ventures combines capital, expertise, infrastructure, and the GE global network to help accelerate the growth of businesses.
Elizabeth Swanson
Director, Human Resources of Cue
Elizabeth Swanson is a Director, Human Resources at Cue Health Inc.
Follow Elizabeth Swanson:
About Cue: Cue helps users track their health at the molecular level, revealing the interplay of activity, food, and sleep.
Andrew Hudak
Senior Director, Program Management of Cue
Andrew Hudak is the Sr. Director of Program Management at Cue Inc.
Follow Andrew Hudak:
About Cue: Cue helps users track their health at the molecular level, revealing the interplay of activity, food, and sleep.
Deborah Morris
Director of Regulatory and Clinical Affairs of Cue
Deborah Morris is the Director of Regulatory and Clinical Affairs at Cue Health Inc.
Follow Deborah Morris:
About Cue: Cue helps users track their health at the molecular level, revealing the interplay of activity, food, and sleep.
Steve Venz
Director of Automation of Cue
Steve Venz is the Director of Automation at Cue Inc.
Follow Steve Venz:
About Cue: Cue helps users track their health at the molecular level, revealing the interplay of activity, food, and sleep.
Edward Ludwig
Non-Executive Chairman of the Board of Directors of POCARED Diagnostics
Edward Ludwig has been a Member of the Board of Directors of Boston Scientific since March 2014. Edward is the former Chairman of the Board of Directors of Becton, Dickinson and Company (“BDX”), a global medical technology company, having served in that position from February 2002 through June 2012. Edward also served as BDX’s Chief Executive Officer from January 2000 to September 2011 and as its President from May 1999 to December 2008. Edward joined BDX as a Senior Financial Analyst in 1979. Prior to joining BDX, Edward served as a Senior Auditor with Coopers and Lybrand (now PricewaterhouseCoopers) where he earned his CPA and as a financial and strategic analyst at Kidde, Inc. Edward serves as Lead Director on Aetna Inc.’s Board of Directors and chairs its Finance Committee and is a Member of the Board of Directors of Xylem, Inc. Edward serves as the Non-Executive Chairman of POCARED, a privately held firm in Israel. Edward is also a Member of the Board of The Center for Higher Ambition Leadership, which is dedicated to studying, documenting and advancing the principals of Higher Ambition Leadership that drive the most successful enterprises in terms of longer term shared value creation. Edward served as a Member of the Board of Trustees of the College of the Holy Cross (2005-2013), and the Columbia Business School Board of Overseers (2010-2015). Edward also served as a Member of the Board of Trustees of the Hackensack University Medical Center Network Board of Trustees. Edward received a B.A. degree in Economics and Accounting from The College of the Holy Cross and a MBA degree from Columbia University.
Follow Edward Ludwig:
About : Revolutionizing infections disease practice with culture-free microbiology.
David Wetherell
Founder & Managing Director of Biomark Capital
Follow David Wetherell:
About Biomark Capital: Biomark Capital provides venture funding and assistance to early, mid, and late-stage life science companies.
Bryant E. Fong
Managing Director of Biomark Capital
Mr. Fong is a founding Managing Director at Biomark Capital, a life sciences private equity fund formed in 2013. Prior to BioMark Capital, Mr. Fong was a Managing Director and General Partner at Burrill & Company, where he spent almost 16 years investing in and managing investments in private and public companies in the biotechnology industry. Some of Mr. Fong’s most notable investments include Pharmasset (VRUS), Novadaq Technologies (NVDQ), Galapagos (GLPG), Morphotek, Ceptaris Therapeutics, and Ferrokin Biosciences. Prior to joining Burrill & Company, Mr. Fong held positions as a research scientist with two early stage biotechnology companies located in the San Francisco Bay Area. Mr. Fong currently serves on the Boards of Directors of a number of life science companies including NEOS Therapeutics, Neurotech Pharmaceuticals, ADMA Biologics (ADMA), Acusphere (ACUS), i2Dx, WaveTec Vision, JHL Biotech, and Nora Therapeutics. Mr. Fong earned his bachelor’s degree with honors in Molecular and Cell Biology-Biochemistry from the University of California, Berkeley.
Follow Bryant E. Fong:
About ADMA Biologics, Biomark Capital: Biomark Capital provides venture funding and assistance to early, mid, and late-stage life science companies.
Douglas Lind
Managing Director of Biomark Capital
Douglas Lind joined Burrill & Company as a Managing Director in the Venture Group in January 2012. Previously he served as Managing Director at GBP Capital, a Greenwich, Connecticut-based healthcare venture firm. He has more than 20 years experience in the life sciences industry, ranging from the practice of clinical medicine to work as a top tier Wall Street equity research analyst and venture capitalist. Throughout his career he has focused on identifying promising disruptive technologies and visionary leadership that offer high value solutions to pressing medical needs. He served as senior biotechnology equity research analyst at Morgan Stanley from 1997 through 2002 and at PaineWebber from 1995 to 1997. His coverage of large and small capitalization biotechnology companies included Amgen, Biogen, Celera (acquired by Quest Diagnostics), Centocor (acquired by Johnson & Johnson), Chiron (acquired by Novartis), IDEC Pharmaceuticals (acquired by Biogen), ImClone (acquired by Bristol-Myers Squibb), MedImmune (acquired by AstraZeneca), Agouron (acquired by Warner Lambert), Axys Pharmaceuticals (acquired by Celera) and Millenium Pharmaceuticals (acquired by Takeda Pharmaceuticals). Dr. Lind is a graduate of the University of Iowa College of Medicine. He served as an attending physician at St. Elizabeth’s Hospital in Boston, a major teaching affiliate of Tufts University School of Medicine, where he completed residency training in internal medicine. He currently serves on the board of directors of Lentigen, MabVax, TMune, HyperMed Imaging, and Spectral Image.
Follow Douglas Lind:
About Biomark Capital: Biomark Capital provides venture funding and assistance to early, mid, and late-stage life science companies.
Sergey Axenovich
Director of Biomark Capital
Sergey Axenovich joined Biomark Capital in November 2013. Before joining Biomark Capital, Dr. Axenovich was a Director at Burrill & Company where he was responsible for sourcing, evaluating, and executing investment transactions. Previously, Sergey managed the cancer drug discovery program and associated corporate collaborations at PPD. He began his research career at Genome Therapeutics. Subsequently, he received his MBA from the University of California, Berkeley Haas School of Business. Sergey has a Ph.D. in Molecular Genetics from the University of Illinois, Chicago and an undergraduate degree in Molecular Biology from Moscow University.
Follow Sergey Axenovich:
About Biomark Capital: Biomark Capital provides venture funding and assistance to early, mid, and late-stage life science companies.
Joshua Zelig
Director of Biomark Capital
Joshua Zelig joined Burrill & Company as a Director in the Venture Group in 2011. Prior to joining the Company, Mr. Zelig was an Associate Partner at GBP Capital, a Greenwich, Connecticut-based healthcare venture firm. In that capacity he was responsible for sourcing, evaluating, and executing investment transactions and new business opportunities. Additionally, Mr. Zelig managed the firm’s intellectual property portfolios, oversaw the company’s operations, and worked closely with portfolio companies in setting and delivering strategic objectives. Previously, Mr. Zelig was an Equity Research associate at Morgan Stanley where he covered biotech and consumer stocks. He later worked in real estate management, acquisition, and due diligence on behalf of a number of large private real estate companies as well as public REITs. Mr. Zelig is a graduate of Yeshiva University, Sy Syms School of Business, where he received a Bachelor of Science in Finance.
Follow Joshua Zelig:
About Biomark Capital: Biomark Capital provides venture funding and assistance to early, mid, and late-stage life science companies.
Nurettin Dag
Director Of Engineering of Flatiron Health
Follow Nurettin Dag:
About Flatiron Health: Flatiron Health is a healthcare technology company that aims to improve lives by learning from the experience of every cancer patient.
Julia Morton
Senior Director, Customer Success of Flatiron Health
Julia leads the Customer Success function at Flatiron Health. The Flatiron team is building a disruptive, oncology-specific software platform that connects cancer centers across the world on a common technology infrastructure to address key healthcare challenges, dramatically improving treatment and accelerating research. Julia’s team is responsible for helping oncologists be successful on Flatiron’s software and partnering with customers to achieve their strategic objectives around practice sustainability and growth. The Customer Success team delivers Account Management, Customer Support, Technical Support Engineering, Communications and Training & Content services to oncology practices nationwide. Prior to joining Flatiron, Julia led the Physician Onboarding function at ZocDoc, and worked as a consultant to healthcare and technology clients growing their businesses and improving customers’ experience. She holds a BA and an MBA from Harvard.
Follow Julia Morton:
About Flatiron Health: Flatiron Health is a healthcare technology company that aims to improve lives by learning from the experience of every cancer patient.
Evan Estola
Director of Engineering of Flatiron Health
Follow Evan Estola:
About Flatiron Health: Flatiron Health is a healthcare technology company that aims to improve lives by learning from the experience of every cancer patient.
Lesley Plotkin
Director, Research Marketing of Flatiron Health
Follow Lesley Plotkin:
About Flatiron Health, Flatiron Health, Flatiron Health: Flatiron Health is a healthcare technology company that aims to improve lives by learning from the experience of every cancer patient.
Carlos Aguilar
Director, Forward Deployed Engineering of Flatiron Health
Director, Forward Deployed Engineering at Flatiron Health.
Follow Carlos Aguilar:
About Flatiron Health: Flatiron Health is a healthcare technology company that aims to improve lives by learning from the experience of every cancer patient.
Nathaniel Brown
Director of Product Marketing and Strategy of Flatiron Health
Nathaniel Brown is the director of product marketing and strategy at Flatiron Health.
Follow Nathaniel Brown:
About Flatiron Health: Flatiron Health is a healthcare technology company that aims to improve lives by learning from the experience of every cancer patient.
Ayelet Akselrod-Ballin
Director of AI of Zebra Medical Vision
Ayelet Akselrod-Ballin is the Director of AI at Zebra Medical Vision Ltd.
Follow Ayelet Akselrod-Ballin:
About Zebra Medical Vision: Zebra Medical Vision is a medical imaging insights platform.
Denis R. Burger
Lead Director of Trinity Biotech
Co-founded Trinity Biotech in June 1992 and acted as Chairman from June 1992 to May 1995. He is currently Vice Chairman of CytoDyn Inc. an anti retroviral therapeutics, OTC:BB listed company and is also non-executive director of Aptose Biosciences, Inc, a cancer therapeutics, TSX and NASDAQ listed company. Until March 2007, Dr Burger was the Chairman and Chief Executive Officer of AVI Biopharma Inc, a NASDAQ listed biotechnology company. He was also a co-founder and, from 1981 to 1990, Chairman of Epitope Inc. In addition, Dr Burger has held a professorship in the Department of Microbiology and Immunology and Surgery (Surgical Oncology) at the Oregon Health and Sciences University in Portland. Dr Burger received his degree in Bacteriology and Immunology from the University of California in Berkeley in 1965 and his Master of Science and PhD in 1969 in Microbiology and Immunology from the University of Arizona
Follow Denis R. Burger:
About Trinity Biotech: Trinity Biotech has actively pursued the aim of becoming a leading player in the international diagnostics.
Denny Moynihan
Senior Director of Quest Diagnostics
Denny Moynihan is a senior director at Quest Diagnostics.
Follow Denny Moynihan:
About Quest Diagnostics: Quest Diagnostics is a clinical laboratory that offers diagnostic testing, services, and information.
Kelly Curia-Schmidt
Executive Director of Vision Care Sales of Bausch & Lomb
Follow Kelly Curia-Schmidt:
About Bausch & Lomb: Bausch & Lomb is an eye health company bringing visionary Ideas to Eye Health.
Paturi V. Rao
Co-Founder and Director of DiabetOmics
Dr. Rao is co-founder and director for DiabetOmics operations in India and Asia. Dr. Rao is Professor and Chief of Endocrinology at Nizam’s Institute of Medical Sciences University in Hyderabad, India. Dr. Rao served as Secretary of Research Society for the Study of Diabetes in India (RSSDI) from 1993-2007. RSSDI is the largest diabetes care provider’s organization in Asia, with more than 7000 member diabetologists. Dr. Rao has served as principal investigator on several key international clinical studies in diabetes, including ORIGIN, DREAM, and several phase-II and phase-III clinical trials for Novo Nordisk, Eli Lilly, Aventis, Merck Scharpe & Dohme, Novartis, and Johnson & Johnson. Dr. Rao serves on the advisory committees of the Indian Council of Medical Research, Department of Science & Technology, and several pharmaceutical companies.
Follow Paturi V. Rao:
About DiabetOmics: DiabetOmics is a medical diagnostics company that provides non-invasive assessment and management of personalized health and diabetes risk.
Ron Zwanziger
Co-Founder, Chief Executive Officer, Chairman, and Director of LumiraDx
Ron Zwanziger, a strategic visionary and entrepreneur, is the CEO of LumiraDx, which he co-founded in 2014. He previously founded and led numerous successful diagnostic firms, including Alere, Inverness Medical Technology (which was acquired by Johnson & Johnson in 2001), and MediSense, the first company to introduce an electrochemical glucose sector. He currently serves on the Board of Directors of several private companies.
Follow Ron Zwanziger:
About LumiraDx: LumiraDx is a healthcare company that manufactures a diagnostic platform to support a menu of tests with lab comparable performance.
Emil Patel
Director – IT Engineering of The University of Texas M.D. Anderson Cancer Center
Emil Patel serves as director of IT engineering at MD Anderson Cancer Center.
Follow Emil Patel:
About The University of Texas M.D. Anderson Cancer Center: The MD Anderson Cancer Center is one of the original three comprehensive cancer centers in the United States established by the National
Sam Hanash
Director of MD &erson’s Red & Charline McCombs Institute for the Early Detection & Treatment of The University of Texas M.D. Anderson Cancer Center
I was recruited to join MD Anderson in July 2012 to lead the Red and Charline McCombs Institute for Cancer Early Detection and Treatment of Cancer. My interests and expertise focus on the development and application of integrated approaches for the molecular profiling of cancer, with emphasis on the application of proteomics technologies for the development of blood based markers to identify subjects at increased risk of developing cancer and markers for early detection of cancer and for tumor classification. The work involves sorting through tens of thousands of protein forms in the blood most of which occur at exceedingly low abundance to identify those that are most relevant to particular cancer types. I serve as program principal investigator for many multi-investigator projects aimed at discovery and validation of cancer markers. I led a consortium of investigators working on molecular profiling of lung cancer to identify molecular risk factors for developing lung cancer among smokers as well never smokers that can be used to develop a blood test for lung cancer risk. Another goal is to develop blood based markers for the early detection of lung cancer. I have also led similar efforts to identify markers for the early detection of other cancers notably breast, ovarian, pancreas and colon. I pioneered strategies for the discovery of cancer markers which include molecular profiling of blood that was collected one or more years prior to a diagnosis of cancer to determine the changes that can be detected in blood that could be used for assessing risk or for detecting cancer at an early stage. Another approach pioneered is the use of mouse models of cancer in which cancer causing genes are turned on and blood is collected serially to identify the earliest changes in the blood that occur with tumor development. Findings from mouse studies are validated using human blood to confirm the relevance of these markers for the early detection of cancer in humans.
Follow Sam Hanash:
About The University of Texas M.D. Anderson Cancer Center: The MD Anderson Cancer Center is one of the original three comprehensive cancer centers in the United States established by the National
Kenna Mills Shaw
Executive Director, Institute for Personalized Cancer Therapy of The University of Texas M.D. Anderson Cancer Center
Kenna Shaw is executive director of the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (Khalifa Institute). She joined The University of Texas MD Anderson Cancer Center in 2013, bringing an extensive background in science leadership and education. Prior to joining MD Anderson, Kenna Shaw spent four years with The Cancer Genome Atlas (TCGA), a flagship project of the National Cancer Institute focused on accelerating understanding of the molecular basis of cancer. Kenna Shaw earned undergraduate degrees in Spanish and Biology at the College of William and Mary, and completed her doctoral degree in cell and developmental biology at Harvard University.
Follow Kenna Mills Shaw:
About The University of Texas M.D. Anderson Cancer Center: The MD Anderson Cancer Center is one of the original three comprehensive cancer centers in the United States established by the National
Ed Klosterman
Director, US Field Service Operations of bioMerieux
Ed Klosterman is the Director of U.S. Field Service Operations for bioMérieux, a leading medical diagnostic company. With his undergrad in engineering / business, he completed his MBA at Webster University. Ed is a standout leader that has directed high performing teams built for achievement and agility, while guiding an industry recognized customer support operation. With greater than 20 years of experience in the global medical diagnostic service industry, Ed is passionate about his work and contribution toward improve healthcare in America. On a personal level, Ed sits on the board for the Boys & Girls Club and active within his community speaking at high schools about many topics, including careers in healthcare.
Follow Ed Klosterman:
About bioMerieux: bioMérieux develops and produces in vitro diagnostic solutions for private and hospital laboratories, mainly for the diagnosis.
Eric Byington
Managing Director of 10.10.10
Follow Eric Byington:
About 10.10.10: 10.10.10 gives impact entrepreneurs the context and tools to develop market-based solutions.
Larry Papasan
Chairman of the Board of Directors of MEDOVEX
Larry Papasan is the retired President of Smith & Nephew Orthopedics. Larry joined Smith & Nephew in July, 1991 as President of the Ortho Division and retired December 31, 2002. During this 11-1/2 year period, the Division grew in sales from $300 million to $650 million while growing profitability at over 15% per year. Smith & Nephew Orthopedics is a company with manufacturing in Memphis and Germany. Larry was responsible for Research and Development, Manufacturing, Marketing, Sales and all Administrative functions of the Company during his 11-1/2 year tenure as President. Larry then worked for Smith & Nephew as a Director and Lobbyist until the end of 2005. Prior to joining Smith & Nephew, Larry was President of Memphis Light, Gas & Water Division from 1984 until his retirement in 1991. Larry was employed by MLG&W for 28 years. Larry has been a Member of the Board of Directors and Chairman of the Board of Directors of BioMimetic Therapeutics [NasdaqGM:BMTI] since August 2005. BioMimetic Therapeutics, Inc. is developing and commercializing bio-active recombinant protein-device combination products for the healing of musculoskeletal injuries and disease, including orthopedic, periodontal, spine and sports injury applications. Larry has also served as a Member of the Board of Directors at Reaves Utility Income Fund [NasdaqCM:UTG], a closed-end management investment company, since February 2003, SSR Engineering, Inc. and AxioMed Spine Corporation. Larry graduated from Mississippi State University in 1963 with a Bachelor of Science in Civil Engineering. Larry has completed numerous professional development courses, including the American Management Association Management course, Senior Management course and President’s course. Larry has been very active in the Memphis Community and was General Campaign Chairman of United Way in 1987 and Chairman of the Board from 1990-92, President of Kiwanis Club and President of Junior Achievement. Currently, he is involved with several organizations, some of which are BioMimetic Therapeutics, Inc., BioMedical Tissue Technologies, Ltd. and the Shelby Farms Park Conservancy. Larry is married and has two grown children and five grandchildren. He is an avid golfer.
Follow Larry Papasan:
About MB Venture Partners: MEDOVEX’s management team and board of directors are highly experienced healthcare professionals in all functional areas
Maria Berkman
Director of Broadview Ventures
Maria Berkman, MD, MBA, is a Director, and Head of the MedTech practice at Broadview Ventures. Maria shares responsibility for all aspects of Broadview’s investment activity, from identification and screening of new opportunities, through due diligence, negotiation of deal structure, and portfolio company board involvement. Prior to joining Broadview Ventures, Maria was a management consultant at Monitor Group (now Monitor Deloitte), where she specialized in life sciences with a focus on corporate, franchise, and asset-level commercialization strategy and competitive strategic planning for a broad range of BioPharma and MedTech clients. Prior to joining Monitor Group, Maria trained within the Partners HealthCare System at Newton Wellesley Hospital in General Surgery. Maria earned an MD from the UCLA School of Medicine, graduating Alpha Omega Alpha with a research focus in cardiothoracic and trauma surgery, and earned an MBA from the Anderson School of Management at UCLA. Maria serves on the boards of 480 Biomedical, Adient, BioKier, Cardialen, FineHeart, Vascular Graft Solutions, Vectorious, and Zumbro Discovery, and previously served on the boards of Apama (acquired by Boston Scientific) and Capricor (NASD:CAPR). In addition to her role at Broadview Ventures, Maria contributes time as a SBIR/STTR grant reviewer for the National Science Foundation and is a Strategic Advisory Board Member for the RAD BioMed Accelerator in Tel Aviv, Israel.
Follow Maria Berkman:
About Broadview Ventures, National Science Foundation: Broadview Ventures invests in businesses that focus on the development of technology solutions in cardiovascular and neurovascular diseases.
Christopher de Souza
Director of Broadview Ventures
Christopher de Souza, PhD, shares responsibility for the day-to-day operations of Broadview Ventures, including business development strategy, identification and screening of new investment opportunities, negotiation of partnering terms and deal structure, as well as portfolio company board involvement. He leverages 20 years of experience in biopharmaceutical R&D, business development and corporate strategy to help meet the Broadview Ventures mission. Christopher started his pharmaceutical career at Novartis where he was a senior scientist in the Metabolic and Cardiovascular Diseases group and then Director of Strategic Alliances with responsibilities for the therapeutic area strategy, business development and alliance management. After Novartis, Christopher was VP of Business Development at SkyePharma US Inc, a drug delivery company, where he was responsible for out-licensing SkyePharma’s clinical assets and drug delivery technologies. Christopher also founded a business development consulting practice with several clients including JSB-Partners, Diagnostics For All and Metaome.
Follow Christopher de Souza:
About Broadview Ventures: Broadview Ventures invests in businesses that focus on the development of technology solutions in cardiovascular and neurovascular diseases.
Christopher Colecchi
Managing Director of Broadview Ventures
Christopher Colecchi is the Managing Director of Broadview Ventures, the philanthropic venture investing arm of the Paris-based Leducq Family Trust. Broadview’s mission is to accelerate the development of cures for cardiovascular diseases through investments in promising early stage companies. Previously, Chris was the Vice President for Research Ventures and Licensing at Partners Healthcare–an integrated health system founded in 1994 by the Harvard-affiliated Brigham and Women’s Hospital and Massachusetts General Hospital. Chris led business development, technology transfer, and commercialization activities at Partners and managed efforts to establish strategic alliances with the life sciences industries. He also created the Partners Innovation Fund–an internal venture capital fund that makes investments in early stage science from Partners hospitals to create start-up companies to improve patient care. Earlier in his career, Chris was the Director of Clinical Trials and Industrial Relations for the Massachusetts General Hospital and Director of Clinical Monitoring for a clinical research organization (CRO) at which he oversaw the set-up and management of multi-center, industry-sponsored clinical trials at several hundred sites throughout the U.S. and Canada. Within these roles, Chris has worked directly with most of the major international pharmaceutical and biotechnology companies as well as many in the device arena.
Follow Christopher Colecchi:
About Broadview Ventures: Broadview Ventures invests in businesses that focus on the development of technology solutions in cardiovascular and neurovascular diseases.
Nichole Schiffer
Director of Operations of Broadview Ventures
Nichole manages day-to-day business operations, office administration, triaging of incoming investment opportunities, and meeting and event planning. Nichole also supports the investment team in its day-to-day operations.
Follow Nichole Schiffer:
About Broadview Ventures: Broadview Ventures invests in businesses that focus on the development of technology solutions in cardiovascular and neurovascular diseases.
Mark Mactas
Board of Director of Envision Healthcare
Mark Mactas was most recently deputy chairman, president and chief operating officer for Towers Watson until his retirement in 2011. He was formerly chairman and chief executive officer of Towers Perrin (before it merged with Watson Wyatt) from 2001 to 2009. With 14,000 associates around the world, Towers Watson offers professional services in benefits, talent management, rewards, and risk and capital management. Mark is currently vice chairman of the board of Save the Children, where he has been a trustee since 2006. Since 2011, he has served on the Board of Trustees and Executive Committee of Lehigh University. In 2013, he joined the Envision Healthcare board, which offers an array of healthcare-related services to consumers, hospitals, healthcare systems, health plans and local, state and national government entities. He also was president of the Conference of Consulting Actuaries and served on its board as well as that of the American Academy of Actuaries.
Follow Mark Mactas:
About : Envision Healthcare offers array of healthcare-related services to consumers, hospitals.
Carol J. Burt
Board of Director of Envision Healthcare
Follow Carol J. Burt:
About : Envision Healthcare offers array of healthcare-related services to consumers, hospitals.
Richard Schnall
Board of Director of Envision Healthcare
Rick Schnall is the Partner at Clayton Dubilier & Rice.
Follow Richard Schnall:
About CD&R LLP: Envision Healthcare offers array of healthcare-related services to consumers, hospitals.
James Shelton
Board of Director of Envision Healthcare
James D. Shelton was elected to Envision’s Board of Directors in May 2015. Mr. Shelton served as Chairman, Chief Executive Officer and President of Triad Hospitals, Inc., from 1999 until its sale in 2007. Prior to his leadership at Triad Hospitals, Mr. Shelton held numerous executive positions at Columbia/HCA Healthcare Corporation, serving as President of the Pacific Group from 1998 to 1999 and President of the Central Group from 1994 to 1998. Mr. Shelton serves as Chairman of the Board of Directors of Omnicare, Inc., and also was interim Chief Executive Officer of Omnicare from July through December 2010. He also is a member of the Board of Directors of Ventas, Inc. Mr. Shelton earned a bachelor’s degree from Louisiana State University and a Master of Science degree in public administration from University of Missouri-Columbia.
Follow James Shelton:
About : Envision Healthcare offers array of healthcare-related services to consumers, hospitals.
Karthikeyan Madathil
Director of Algorithms & Analytics and Director, India Operations of Atonarp
Follow Karthikeyan Madathil:
About Atonarp: Atonarp combines electronics and data processing algorithms for chemical composition analysis.
Boumsellek Said
Senior Director – Instrumentation of Atonarp
Follow Boumsellek Said:
About Atonarp: Atonarp combines electronics and data processing algorithms for chemical composition analysis.
Nabil Saad
Sr. Director – Marketing & Business Development of Atonarp
Follow Nabil Saad:
About Atonarp: Atonarp combines electronics and data processing algorithms for chemical composition analysis.
Jim Z. Lu
CEO and Medical Director of GoPath Laboratories LLC
Jim Lu, M.D., Ph.D., is the founder, CEO, and Medical Director for GoPath Laboratories. His focus is primarily on business development while he remains active with GI/Liver pathology cases and molecular test development. He received his medical degree from Wannan Medical College in Anhui, China. Afterward, he attended Johns Hopkins School of Medicine where he earned his Ph.D. in Molecular Medicine. He also successfully completed his residency and fellowship training in GI/Liver and transplant pathology at the University of Pittsburgh Medical Center. Dr. Lu has been practicing in this area of expertise for more than 15 years.
Follow Jim Z. Lu:
About GoPath Laboratories LLC: GoPath is a fully equipped, CAP Accredited and CLIA Certified Anatomic Pathology, Clinical Pathology and Molecular Diagnostic laboratory
Stephen Kendig
Managing Director, Growth of Babylon
Stephen Kendig, Chief Commercial Officer and EVP of SoloHealth Inc. He is an award-winning executive with experience spanning sales management, finance, global marketing, supply chain, manufacturing, R&D, market research, regulatory and legal divisions. Formerly Chief Operating Officer, Kendig was promoted to EVP, Chief Commercial Officer, in early 2012 where he is responsible for the long-term revenue, growth and strategic direction of SoloHealth. As such, he oversees the sales and marketing teams, as well as expands the company’s retail and advertising partners. Throughout his career, Kendig has had a successful track record of leading new product development initiatives from ideation through commercialization. Prior to SoloHealth, Kendig worked with the eye care division of Novartis (NVS), where he held various executive positions across research, process engineering, new product development and global project management. During his tenure at Novartis, he managed a new product portfolio of over $200MM, led global product launches, filed five patent disclosures, and was awarded the 2006 executive award. Stephen has a Mechanical Engineering Degree from the Georgia Institute of Technology. He received his Master’s Degree in Business Administration from Georgia State University.
Follow Stephen Kendig:
About Babylon, illuma Care Connections: Babylon is a world leading, digital-first, value-based care company.
William Biggs
Sr. Director & Site Head of Guardant Health
Follow William Biggs:
About Guardant Health: Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs in oncology.
Eric Boutin
Managing Director of dRx Capital
Eric Boutin was Founder | CEO of Evolve, acquired by HubSpot (NYSE: HUBS). He was Founder | CEO of Good Start Genetics, acquired by Invitae (NYSE: NVTA). He was Founder | VP of Flex Pharma, IPO (NASDAQ: FLKS). Eric was an EIR at Longwood Fund, and Founder of HBS Angels Boston. He holds a BA from Duke University, and an MBA from Harvard.
Follow Eric Boutin:
About dRx Capital: Novartis Digital Health Venture Capital
Stella Sarraf
Chief Executive Officer, Founder & Director of Amydis, Inc.
Dr. Sarraf founded Amydis in 2013 after seeing a clinical need for diagnostics that can enable early detection of neurodegenerative diseases. She brings a blend of large pharmaceutical operational expertise, venture investment background and entrepreneurship to Amydis. Dr. Sarraf is viewed as a visionary with a deep understanding of “cradle to grave” and the necessary components to achieve success from product concept through to commercialization. Previously, she spent 10 years in Venture Capital at Foresite Capital Management and Prospect Venture Partners, both growth capital healthcare funds with over $1B dollars in assets under management. Some of the successful investments and exits by Foresite with Dr. Sarraf’s involvement included Wavetec Vision (sold to Alcon in 2014), Ambit Biosciences (acquired by Daiichi Sankyo in 2014 for $410M) and Auspex Pharmaceuticals (sold to Teva for $3.5B in 2015). At Prospect, she performed scientific, regulatory and commercial diligence on more than 400 investment opportunities from companies in therapeutic and diagnostic areas including the neurological and cognitive disorder space. Earlier in her career, Dr. Sarraf worked at Merck Research Laboratories in Rahway, New Jersey as a senior research chemist responsible for creating the chemical synthesis of a novel drug for translation from the bench to production scale.
Follow Stella Sarraf:
About Amydis, Inc., Scientific Consulting, Spinogenix, Spinogenix: A pharmaceutical company focused on developing innovative chemistry to detect diseases that involve the presence of amyloid proteins.
Feyza Sancar
Associate Director, Evidence Generation and Publications of Exact Sciences
Dr. Sancar earned her PhD in Neuroscience from the University of Wisconsin-Madison, and held postdoctoral appointments at Northwestern University and the University of Illinois at Chicago. She has authored 8 papers and received several awards and fellowships, including a pre-doctoral fellowship from the American Epilepsy Society and a post-doctoral Visiting Scholar Fellowship from the Scientific and Technical Research Council of Turkey. In addition to over 11 years of research experience in basic and biomedical sciences, she most recently served as a Scientific Editor for the Cell Press journal Neuron.
Follow Feyza Sancar:
About Exact Sciences: Exact Sciences is the developer and manufacturer of Cologuard, a non-invasive screening test for the early detection of colorectal cancer.
Richard Berman
Director of Advaxis
Follow Richard Berman:
About Advaxis: Advaxis is a developer of multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer.
Scott Donald
Director of Clinical Services of Health Information Designs
Scott Donald joined Health Information Designs as Director of Clinical Services in 2012.
Follow Scott Donald:
About Health Information Designs: Health Information Designs is a clinical service company that markets drug utilization review services to state Medicaid agencies.
Adam Pollet
Board of Directors of MATTER
Adam Pollet oversees the state agency tasked with growing Illinois’ economy. Prior to his appointment by Governor Pat Quinn in November 2012, Pollet served as deputy director for the Illinois Office of Trade and Investment where he led the state’s export and foreign direct investment activities. Before joining the state in 2011, Pollet was a consultant at McKinsey & Co. in Chicago where he served client companies in the firm’s strategy and operations practices focused on the energy, transport, logistics and automotive sectors. A graduate of Harvard Law School and Stanford University, Pollet worked for the United Nations focusing on international economic development including customs modernization and trade facilitation in Afghanistan.
Follow Adam Pollet:
About : MATTER provides the healthcare industry with technology solutions to improve products and services.
Stan Abel
Chairman Of The Board Of Directors of SiteOne Therapeutics
Follow Stan Abel:
About SiteOne Therapeutics: SiteOne Therapeutics is a San Francisco-based company that develops novel therapeutics and diagnostics.
Kristen M. Lorentz
Director, Center for External Innovation (Business Development) of Takeda
Follow Kristen M. Lorentz:
About Takeda: Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company in Japan.
Bin Li
Director of Computational Biology, Takeda Data Science Institute of Takeda
Bin Li is a director of computational biology at Takeda Data Science Institute. His team provides computational supports on translational and biomarker research for various Takeda compounds. They develop computational methods for exploratory data analysis, build translational predictive models and data repositories for patient stratification and disease indication selection efforts. His team is also responsible for method evaluation and pipeline building for various NGS platforms, including WES, RNA-seq, and targeted NGS panels.
Follow Bin Li:
About Takeda: Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company in Japan.
Krishnan Allampallam
Global Marketing Director of Chembio Diagnostic Systems Inc.
Krishnan Allampallam serves as the Global Marketing Director at Chembio Diagnostic Systems, Inc.
Follow Krishnan Allampallam:
About Chembio Diagnostic Systems Inc.: Chembio Diagnostics, Inc. develops, manufactures, licenses and markets proprietary rapid diagnostic.
Michael Martin
Senior Investment Director of Takeda Ventures, Inc.
Dr. Martin joined TVI in April 2015 and is based in San Diego, CA. His professional background includes pharma business development and broad R&D experiences with an integral role in the discovery and preclinical/clinical development of 17 innovative investigational drugs and 2 commercial products. Dr. Martin was most recently a member of Global Licensing and Business Development at Takeda, heading efforts for globally sourcing and transacting technologies and early stage pipeline programs. Dr. Martin joined Takeda in January 2012 through the acquisition of Intellikine where he was Vice President of Preclinical Development. Additionally, he has held executive and senior management and scientific positions with TargeGen (acquired by Sanofi-Aventis), Arena Pharmaceuticals, and Monsanto Corporation. Dr. Martin earned his doctorate in Medicinal Chemistry from the University of Illinois and holds a M.S. degree in analytical chemistry and B.S. degrees in Chemistry and Mathematics.
Follow Michael Martin:
About Takeda Ventures, Inc.: Takeda Ventures focuses on high-caliber therapeutic and platform based opportunities around the world.
Parker MacDonell
Managing Director of Rev1 Ventures
Follow Parker MacDonell:
About Ohio TechAngels Fund, Rev1 Ventures: Rev1 Ventures is an investor startup studio that combines capital and strategic services to help startups scale and corporates innovate.
Michael Kindrat-Pratt
Managing Director of Rev1 Ventures
Michael Kindrat-Pratt is Managing Director at Rev1 Ventures.
Follow Michael Kindrat-Pratt:
About Ohio TechAngels Fund, Rev1 Ventures: Rev1 Ventures is an investor startup studio that combines capital and strategic services to help startups scale and corporates innovate.
Alicia Oddi
Managing Director of Rev1 Ventures
Alicia Oddi creating new websites and social media campaigns, to producing VentureNEXT, the celebration of Central Ohio’s startups, Alicia’s enthusiasm and excitement about Rev1 clients shines through. With creativity and flair, Alicia shows the rest of Ohio and the country how our entrepreneurs are changing the world. She has a BA in Art History and an MA in Arts Policy and Administration from The Ohio State University.
Follow Alicia Oddi:
About Rev1 Ventures: Rev1 Ventures is an investor startup studio that combines capital and strategic services to help startups scale and corporates innovate.
Bethany George
Sr. Director – Investment Funds of Rev1 Ventures
Bethany’s responsibilities include managing Rev1’s investment, portfolio, and fund processes. As a member of the investment team, she contributes to due diligence and closing processes. Bethany has worked with startups and venture development organizations for more than a decade all over the world. She has a BS degree in Journalism and a MA degree with an emphasis in business, economics, and political science from Ohio University.
Follow Bethany George:
About Rev1 Ventures: Rev1 Ventures is an investor startup studio that combines capital and strategic services to help startups scale and corporates innovate.
